Loading…
← CockpitCompetitor Analysis › ACUTAAS.NS Acutaas ChemicalsOpen in the cockpit ↗

Acutaas ChemicalsACUTAAS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.

≈ A niche Indian pharma-intermediate chemical makerMomentum leader 92
Mkt cap
$3.50B
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$37.6M
20-day average traded
Fwd P/E
63.6×
forward earnings
ROIC−WACC
+15.8 pp
WACC 9.9%
Hurdle
n/a
no reverse DCF
Next earnings
88 days
14 Feb 2027
Close · INR₹3,991
1D+1.2%
1W+1.9%
1M+22.7%
3M+17.7%
6M+38.3%
YTD+134.1%
1Y+133.9%
ATR %4.1%
Beta0.75
52w lowhigh3.4% off high

What Acutaas Chemicals does

Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.

In one line: A niche Indian pharma-intermediate chemical maker.

Products and services

  • Pharma intermediates
  • Specialty fluorochemicals
  • Contrast media intermediates

Customers

  • Global API/generic drug makers
  • Pharma companies

Where it sits in the supply chain

  • Fine chemical synthesis
  • Pharma intermediate manufacturing
  • Sale to API/formulation makers

What could go right

  • Pharma intermediate outsourcing to India
  • Capacity expansion

What could go wrong

  • Customer/product concentration
  • Chemical raw material price swings

Moat: narrow (process know-how, regulatory licence). Specialized fluorination/iodination chemistry capability is not widely replicated by peers.

Headquarters: Ahmedabad, India · Employees: 1,713

Named competitors

Acutaas Chemicals at a glance

Size Acutaas Chemicals (ACUTAAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.50B, the 263rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,991 on 18 Nov 2026.

Performance Over six months the shares gained 38.3%, against +8.1% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 45.2% over the last twelve months (peer median +9.4%); the operating margin is 36.5% (peer median 12.2%).

Valuation It trades at 63.6× forward earnings against a peer median of 19.6× (2nd most expensive of 12).

Capital Return on invested capital runs 15.8 points above its cost of capital (9.9% WACC).

Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026ACUTAAS.NS 139Peer median 111
Six months, rebased to 100: Acutaas Chemicals against the median of its 20 peers (local-currency closes).

Acutaas Chemicals financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹15.9B₹13.4B₹10.1B₹7.17B₹6.17B
Revenue growth—+33%+40%+16%—
Gross profit₹7.68B₹5.31B₹2.73B₹1.58B₹1.60B
EBITDA₹6.23B₹4.84B₹2.34B₹1.30B₹1.25B
Net income₹4.39B₹3.56B₹1.59B₹428M₹833M
Free cash flown/a-₹285M-₹717M-₹1.93B-₹311M
Capital expendituren/a₹3.28B₹1.95B₹3.15B₹964M
Total debt₹151M₹356M₹129M₹2.17B₹36.0M

Quarterly statements and history in the cockpit →

Acutaas Chemicals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%1877ARQTSFZN002262WOCKPHARMAAMLXVRDN2096PPLPHARMA600521000739OGNSLSXENE1513ROVIACUTAAS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Acutaas Chemicals is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×150×ARQTSFZN00226220963320PPLPHARMA000739OGN1513ROVIACUTAAS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Acutaas Chemicals is the large dot.

Acutaas Chemicals competitors and peer comparison

Head to head with its named competitors (ACUTAAS.NS vs NAVINFLUOR.NS vs SRF.NS vs NEOGEN.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Acutaas Chemicals ACUTAAS.NS$3.50B+38%+45%36%63.6×n/a
Navin Fluorine International NAVINFLUOR.NS$5.66B+45%+46%30%51.6×37.0%
Srf SRF.NS$7.77B-7%+20%19%30.0×25.5%
Neogen Chemicals NEOGEN.NS$893M+76%+27%14%123.3×n/a

How Acutaas Chemicals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Acutaas Chemicals against its 20 peers (data as of 18 Nov 2026)
MeasureACUTAAS.NSPeer medianRank in peer set
1-month return+22.7%+2.6%4th highest of 21
6-month return+38.3%+8.1%4th highest of 20
Distance from 52-week high-3.4%-23.4%2nd highest of 21
Revenue growth (TTM)+45.2%+9.4%4th highest of 18
Operating margin36.5%12.2%highest of 16
Forward P/E63.6×19.6×2nd most expensive of 12
ROIC minus cost of capital+15.8 pp+3.7 pp2nd highest of 16
EV / EBITDA52.1×14.5×2nd most expensive of 9
Net debt / EBITDA-0.5×2.4×3rd least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%

Questions

Who are Acutaas Chemicals's main competitors?
Named competitors: Navin Fluorine (NAVINFLUOR.NS), SRF Limited (SRF.NS), Neogen Chemicals (NEOGEN.NS). The cockpit's measured peer set (industry) also includes Shanghai Junshi Biosciences (1877.HK), Arcutis Biotherapeutics (ARQT), Siegfried (SFZN.SW), Parabilis Medicines (PBLS), Jiangsu Nhwa Pharmaceutical (002262.SZ), Wockhardt (WOCKPHARMA.NS).
Is Acutaas Chemicals expensive compared with its peers?
On forward p/e it trades at 63.6× against a peer median of 19.6×, 2nd most expensive of 12 in its peer set.
How has Acutaas Chemicals stock performed?
Over six months to 18 Nov 2026 the shares returned +38.3% against +8.1% for the median peer; over one year +133.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.